Proton Pump Inhibitor (PPI) Inappropriate Use and Economic Burden in Chinese Population

AstraZeneca90,895 enrolled

Overview

This is a descriptive retrospective database analysis study in using database. All patients with a physician PPI prescription will be selected to estimate the PPI inappropriate use.

Study primary objective is to identify the inappropriate use of PPI (overall, outpatient \& inpatient).

Study Type

OBSERVATIONAL

Enrollment

90,895

Conditions

Gastrointestinal Disease

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * All patients in 2015 China Health Insurance Research Association (CHIRA) database. * Patients had PPI prescription during Jan. 2015 to Dec. 2015 will be selected to estimate the PPI inappropriate use. Exclusion Criteria: • Patients without data of treatment information.

Locations (1)

Research Site

Beijing, China

Outcomes

Primary Outcomes

Overall proportion of patient inappropriate use of PPI

Overall number of patient times/courses with PPI inappropriate use (including non-indication use, over maximum daily dose and over maximum duration) divided by the total number of patient-times/courses with PPI use for both outpatients and inpatients.

Time frame: 2015.01-2015.12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.